From Abbott halting sales of the Absorb to the recent FDA approval of the Biotronik Osirio, the last 18 months have seen major shifts in the market landscape for coronary revascularization devices.
In this video Lumere cardiovascular expert Zach Eddy highlights:
- Whether the evidence demonstrates differences in outcomes between the major vendors’ drug-eluting stents (DES)
- How to gain significant leverage when negotiating with DES vendors
- The future landscape, including devices that have gained approval for European use